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Besides a variety of other proteases, polymorphonuclear leukocyte elastase (PMN-E) is also suggested to play a role in the processes
of tumour cell invasion and metastasis. Yet, there is only limited data available on the relation between the tumour level of PMN-E
and prognosis in patients with primary breast cancer, and no published information exists on its relation with the efficacy of response
to systemic therapy in patients with advanced breast cancer. In the present study, we have measured with enzyme-linked
immunosorbent assay the levels of total PMN-E in cytosolic extracts of 463 primary breast tumours, and have correlated their levels
with the rate and duration of response on first-line tamoxifen therapy (387 patients) or chemotherapy (76 patients) in patients with
locally advanced and/or distant metastatic breast cancer. Furthermore, the probabilities of progression-free survival and postrelapse
survival were studied in relation to the tumour levels of PMN-E. Our results show that in logistic regression analysis for response to
tamoxifen treatment in patients with advanced disease, high PMN-E tumour levels were associated with a poor rate of response
compared with those with low PMN-E levels (odds ratio: OR, 0.40; 95% CI, 0.22–0.73; P¼0.003). After correction for the
contribution of the traditional predictive factors in multivariate analysis, the tumour PMN-E status was an independent predictor of
response (P¼0.01). Furthermore, a high tumour PMN-E level was related with a poor progression-free survival (Po0.001) and
postrelapse survival (P¼0.002) in a time-dependent analysis. In contrast, the tumour level of PMN-E was not significantly related with
the efficacy of response to first-line chemotherapy in patients with advanced breast cancer. Our present results suggest that PMN-E is
an independent predictive marker for the efficacy of tamoxifen treatment in patients with advanced breast cancer.
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A complex cascade of proteinases, their receptors and inhibitors,
are required for invasion of tumour cells through the extracellular
matrix, for subsequent metastasis and angiogenesis (reviewed by
Mignatti et al, 1986; Andreasen et al, 1997; Nelson et al, 2000).
Tumour growth and angiogenesis are associated with a strong
inflammatory response via the attraction of macrophages and
polymorphonuclear (PMN) leukocytes by tumour cell-secreted
chemoattractants (Jackson et al, 1997; Lee et al, 1997). In contrast
to their attributed role in exterminating the tumour, recruited
inflammatory cells have been reported to be associated with
tumour progression as well (Scholl et al, 1994; Yamashita et al,
1994, 1996; Shamamian et al, 2000, 2001). The responsible protease
is thought to be PMN-elastase (PMN-E), a serine protease that can
degrade various components of the extracellular matrix directly
(Janoff and Schere, 1968; Mainardi et al, 1980; McDonald and
Kelley, 1980; Barrett, 1981), or indirectly through either the
activation of other proteases (Machovich and Owen, 1990;
Shamamian et al, 2001) or the inactivation of their inhibitors
(Levin and Santell, 1987; Gramse et al, 1984; Wu et al, 1995).
Furthermore, it has been shown that PMN-E is not only produced
by neutrophils but by human breast cancer cells as well (Kao and
Stern, 1986; Yamashita et al, 1994), and moreover can promote the
adhesion of tumour cells to vascular endothelial cells facilitating its
role in tumour metastasis (Nozawa et al, 2000).
In many types of cancer, various tumour-associated proteases
and their inhibitors have been shown to be independent prognostic
factors for relapse-free and overall survival. The most extensively
studied protease systems involve those of the urokinase-type
plasminogen activator (uPA) (reviewed by Andreasen et al, 1997;
Schmitt et al, 1997a; Look and Foekens, 1999) and a variety of
matrix metalloproteinases (MMPs) (reviewed by Duffy et al, 2000;
Nelson et al, 2000). Similarly, high tumour levels of PMN-E have
been reported to be associated with a poor prognosis in patients
with primary breast cancer (Yamashita et al, 1994, 1995a,b;
Foekens et al, 2002) and nonsmall cell lung cancer (Yamashita et al,
1996). In addition to their prognostic relevance in primary disease,
several proteases have been shown to be positive or negative
predictive factors for the efficacy of adjuvant systemic endocrine
therapy or chemotherapy in patients with breast cancer. These
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yproteases comprise uPA (Harbeck et al, 2001, 2002a,b; Ja ¨nicke
et al, 2001), MMP-2 (Talvensaari-Mattila et al, 2001), and several
cathepsins (Ferno ¨ et al, 1994; Billgren et al, 2000; Harbeck et al,
2001).
For breast cancer patients who received systemic therapy for
advanced disease, only three studies are available relating the levels
of serine proteases, that is, uPA (Foekens et al, 1995), human
kallikrein 3 (PSA) (Foekens et al, 1999), or human kallikrein 10
(Luo et al, 2002) to a poor efficacy of first-line tamoxifen
treatment. With respect to the predictive value of serine proteases
for response to chemotherapy in advanced breast cancer, no
published studies are yet available. Taking the prognostic value
and the potential predictive value of serine proteases into account,
we hypothesised that tumour-associated PMN-E might be pre-
dictive for the type of response to systemic treatment in patients
with advanced breast cancer. In order to examine this hypothesis,
we measured PMN-E in cytosols of primary breast tumours and
correlated those with the type of response to first-line treatment
with tamoxifen or chemotherapy in patents with advanced disease.
In addition, we have studied the relation between the tumour level
of PMN-E and the length of progression-free and postrelapse
overall survival.
MATERIALS AND METHODS
Patients and tissues
PMN-E levels were determined in cytosol preparations (as
described below) from 463 primary invasive breast tumours
collected between 1978 and 1989. Selection of samples was based
on the availability of stored cytosol extracts (in liquid nitrogen),
which remained after routine oestrogen receptor (ER) and
progesterone receptor (PgR) analyses. Inoperable T4 tumours
were not included. Our study design was approved by the Medical
Ethical Committee of the Erasmus Medical Center, Rotterdam, The
Netherlands (#MEC-02.953). Patient tissues that were sampled
after neoadjuvant treatment, or obtained from a biopsy specimen,
were excluded. Radiotherapy was given to 366 patients (79%): on
the breast/thoracic wall in 259 patients and/or on the axilla in 222
patients, and/or parasternal and/or supraclavicular lymph nodes in
243 patients. T1 tumours (p2cm) were present in 112 patients
(24%), T2 tumours (42–5cm) in 261 patients (56%), T3 tumours
(45 cm) in 53 patients (11%), and operable T4 tumours in 37
patients (8%). At time of primary tumour removal, 122 patients
(26%) had no involved lymph nodes, 117 patients (25%) had 1–3
nodes involved, 208 patients (45%) had 43 nodes involved, and of
16 patients (3%) information on nodal status was missing.
Pathological examination was carried out as described previously
(Foekens et al, 1989b) and the histological differentiation grade
was coded as poor in 279 patients (60%), moderate in 77 patients
(17%), well in five patients (1%), and unknown for 102 patients
(22%).
Of the 463 patients, 387 received tamoxifen as first-line
treatment, and 76 received polychemotherapy as first-line treat-
ment (cyclophosphamide, methotrexate, 5-fluorouracil (CMF), 59
patients; 5-fluorouracil and cyclophosphamide with adriamycin
(FAC); or with epirubicin (FEC) in 17 patients). The following
inclusion criteria were used for patients who received tamoxifen:
patients with advanced disease who were treated with first-line
tamoxifen therapy (40mgday
 1) and were not exposed to
hormonal treatment at an earlier stage (hormono naive). The
median age of these patients at start of treatment for advanced
disease was 62 years (range 28–91 years). For the 76 patients who
received first-line treatment with CMF, FAC, or FEC for advanced
disease, patients were included if previously not exposed to any
systemic treatment for advanced disease. The median age of these
patients at start of chemotherapy was 53 years (range 31–75
years). The characteristics of the patients who received the
different types of systemic treatment with respect to menopausal
status at the start of systemic treatment for advanced disease, the
first dominant site of disease, the number of patients with
metastatic disease (M1 patients) at primary surgery, disease-free
interval (DFI) between primary tumour removal and first
recurrence, hormone receptor status, and the type and frequency
of adjuvant therapy are listed in Table 1. The median follow-up of
patients still alive after start of systemic therapy for advanced
disease was 54 months (range 9–137 months) in the tamoxifen-
treated patients (38 patients still alive), and 39 months (range 7–80
months) in those who received chemotherapy (four patients still
alive). On first-line tamoxifen therapy, tumour progression
occurred in 385 patients (99%), of whom 256 were subsequently
treated with one or more additional hormonal agents (mostly high-
dose progestins). To date, after the development of hormonal
resistance, 216 patients have received systemic chemotherapy
(CMF, 131 patients; FAC or FEC, 72 patients; or other agents, 13
patients). On first-line chemotherapy, tumour progression oc-
curred in 75 patients (99%) during follow-up. Of these patients, 42
were eventually treated with endocrine therapy (tamoxifen in 28
patients, progestins in 14 patients).
All patients were assessed by standard International Union
Against Cancer criteria for complete and partial remission
Table 1 Characteristics of patients, tumours, and treatment
Tamoxifen Chemotherapy
Characteristic Number
a % Number
a %
Number of patients 387 100 76 100
Menopausal status
b
Premenopausal 76 20 29 38
Postmenopausal 311 80 47 62
M-status
Mo 360 93 72 92
M1 27 7 6 8
Disease-free interval
o1 year 106 27 31 41
X1 year 281 73 45 59
Dominant site of relapse
c
Soft 57 15 19 25
Bone 169 44 17 22
Viscera 161 42 40 53
ER status
d
Negative 49 13 46 61
Positive 338 87 29 38
PgR status
d
Negative 95 25 43 57
Positive 282 73 33 43
Adjuvant treatment
None 309 80 62 82
Hormonal therapy 0 0 2 3
Chemotherapy 78
e 20 12
f 16
aOwing to missing values, numbers do not always add up to 387 and 76, respectively.
bAt start of first systemic treatment for advanced disease.
cIn case of multiple sites,
the site with the worst prognosis was chosen.
dCutoff points used for ER and PgR:
10fmolmg
 1 protein.
eFAC, 14 and CMF, 64.
eFAC, 2 (one combined with hormonal
therapy) and CMF, 10 (one combined with hormonal therapy).
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(stable disease) have a postrelapse survival similar to patients with
partial remission (Ravdin et al, 1992; Foekens et al, 1994a).
Therefore, for overall response, objective response and stable
disease were combined.
Assays of PMN-E, ER, PgR, and total protein
Tumour tissues were stored in liquid nitrogen and pulverised in
the frozen state with a microdismembrator as recommended by the
European Organization for Research and Treatment of Cancer
(EORTC) for processing of breast tumour tissue for cytosolic ER
and PgR determinations (EORTC Breast Cancer Cooperative
Group, 1980). The resulting tissue powder was suspended in
EORTC receptor buffer (10mM dipotassium chloride EDTA, 3mM
sodium azide, 10mM monothioglycerol, and 10% vv
 1 glycerol, pH
7.4). The suspension was centrifuged for 30min at 100000 g to
obtain the supernatant fraction (cytosol). ER and PgR levels were
determined by ligand binding assay or with enzyme immunoassay
as described previously (Foekens et al, 1989a). Cytosol protein was
quantified with the Coomassie brilliant blue method (Bio-Rad
Laboratories, CA, USA) with human serum albumin as a standard.
Taking into account that most of the PMN-E in body fluids or
tissue cytosols is complexed with its main antagonist, the a1-
proteinase inhibitor, we used a commercial two-site enzyme-linked
immunosorbent assay for quantification of total PMN-E levels after
adding a surplus of a1-proteinase inhibitor (100mgml
 1) to each
cytosol (Milenia-PMN Elastase, Milenia Biotec, Bad Nauheim,
Germany).
Statistics
The strength of the associations of PMN-E with continuous
variables was tested with Spearman rank correlation (rs). The
strength of the association of PMN-E (used as a continuous
variable) with other variables (used as grouping variable) was
tested with the nonparametric Wilcoxon rank-sum test or
Kruskal–Wallis test, followed by a Wilcoxon-type test for trend
across ordered groups where appropriate. The length of progres-
sion-free survival was defined as the time from the start of
treatment for advanced disease until the start of next treatment
because of progressive disease or until the time of intercurrent
death. Survival probabilities were calculated by the actuarial
method of Kaplan and Meier (1958). The log-rank test was used to
test for differences between survival curves. Both univariate and
multivariate analyses were performed using the Cox proportional
hazards model. The proportionality assumption was investigated
using a test based on the Schoenfeld residuals (Grambsch and
Therneau, 1994). The residuals were retrieved and a smooth
function of time was fitted and then tested whether there was a
relation. The likelihood ratio test in the Cox regression models was
used to test for differences and interactions. The relation of
predictive factors with response to therapy was examined with
logistic regression analysis. In our search for the best categorisa-
tion of PMN-E, we have used isotonic regression analysis (Barlow
et al, 1972; Foekens et al, 1994b) using the rate of overall response
to tamoxifen treatment as end point. All computations were done
with the STATA statistical package, release 7.0 (STATA Corp.,
College Station, TX, USA). All P-values are two-sided.
RESULTS
PMN-E levels and patient and tumour characteristics
The levels of PMN-E in all the 463 primary breast tumours
analysed ranged from 0.4 to 1667ngmg
 1 protein (median,
6.3ngmg
 1 protein). They were not related with age (rs¼ 0.04,
P¼0.41), but were slightly higher in tumours of premenopausal
patients (median, 6.7ngmg
 1 protein) compared with those of
postmenopausal patients (median, 5.9ngmg
 1 protein) at time of
primary surgery (P¼0.08). PMN-E levels were negatively related
with ER (rs¼ 0.20, Po0.001) and PgR (rs¼ 0.19, Po0.001), but
were not significantly related with tumour size (P¼0.74) or grade
(P¼0.11), or with the lymph-node status of the patient (P¼0.48).
The median level of PMN-E in the tumour cytosols of the 387
patients, who were treated with first-line tamoxifen therapy, was
6.0ngmg
 1 protein (range 0.4–1667ngmg
 1 protein). This is
significantly (P¼0.03) lower than the median level of 7.1ngmg
 1
protein (range 0.7–426ngmg
 1 protein) that was measured in
tumours of the 76 patients who were treated with first-line
chemotherapy. The data are consistent with the higher proportion
of ER-negative tumours in the latter series of patients and the
observed negative relation between the levels of PMN-E and ER.
Univariate analysis for response to treatment in advanced
disease
Of the 387 patients who received tamoxifen as first-line treatment
for advanced disease, 197 (51%) responded (11 complete remis-
sion, 48 partial remission, and 138 stable disease). The median
duration of response in these responders was 15 months. Using
logistic regression analysis, it was shown that older age and
postmenopausal status were associated with a higher rate of
response to tamoxifen treatment than younger age and premeno-
pausal status (Table 2). In patients with a disease-free interval less
than 1 year (35% response; odds ratio, OR set at 1), the fraction of
responding patients was smaller than in patients with a disease-
free interval X1 year (57% response, OR¼2.47). Adjuvant
chemotherapy and first site of relapse were not related to the type
of response on tamoxifen treatment. Patients with ER-positive or
PgR-positive tumours had a more favourable response rate
(OR¼3.73 and OR¼1.73, respectively) than patients with ER-
negative or PgR-negative tumours (OR¼1). As expected, the
traditional prognostic factors nodal status, and size and grade of
the primary tumour were not significantly related with the type of
response to tamoxifen in advanced disease, that is, they were no
predictive factors. When analysing the relation of continuous
tumour PMN-E levels with response, it appeared that there was a
trend towards a lower response rate with increasing levels of PMN-
E( P¼0.07). Using isotonic regression analysis, 20.0ngmg
 1
protein was chosen as cutoff point to classify advanced breast
cancer patients as PMN-E-high and PMN-E-low. Compared with
the 331 patients with low PMN-E levels (54% response (16%
complete and partial remission, 38% stable disease), OR¼1), the
56 patients with high PMN-E levels showed a worse rate of
response (32% response (11% complete and partial remission, 21%
stable disease), OR¼0.40; P¼0.003).
The median postrelapse survival time after the start of tamoxifen
treatment was longer in the 331 patients with low tumour PMN-E
levels compared with the 56 patients with high PMN-E levels (25
and 15 months, respectively). However, the median duration of
response in the 179 responding patients with low tumour PMN-E
levels was not different from that in the 18 responding patients
with high PMN-E levels (median 15 and 17 months, respectively).
In Cox univariate regression analysis using continuous PMN-E
levels, PMN-E was not significantly associated with progression-
free survival (P¼0.51) or postrelapse survival (P¼0.06) when all
failures during the total follow-up period were taken into account
(385 and 349 events in the analyses of progression-free and
postrelapse survival, respectively). However, both in the analysis
for postrelapse and progression-free survival, the proportional
hazards assumption was violated (P¼0.01 and P¼0.04, respec-
tively). This was indicative for a time-dependent relation between
the level of PMN-E and the survival analyses. Since the median
progression-free survival time was 6.7 months and that of
postrelapse survival was 23.5 months, we further explored the
PMN-elastase and tamoxifen therapy in breast cancer
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months in the analysis of progression-free survival (182 events of a
total of 385) and before 20 months in the analysis of postrelapse
survival (167 events of a total of 349). In these analyses, increasing
levels of PMN-E were significantly related with a poor progression-
free (P¼0.01) and postrelapse survival (P¼0.001). Furthermore,
the proportional hazards assumption was no longer violated with
respective P-values of 0.93 in the analysis of progression-free
survival and of 0.64 in the analysis of postrelapse survival.
The results of the Kaplan–Meier analysis for progression-free
and postrelapse survival in all 387 patients, who received first-line
tamoxifen treatment for advanced disease as a function of
dichotomised PMN-E status, are shown in Figure 1A and B,
respectively. Restricting the analyses to the first 6 months for
progression-free survival and to 20 months for postrelapse survival
resulted in hazard ratios (HRs) of 2.02 (Po0.001, Figure 1A) and
1.79 (P¼0.002, Figure 1B), respectively. In the analyses including
all failures over the total follow-up period, the strengths of the
relation of PMN-E with postrelapse survival (P¼0.06) and
progression-free survival (P¼0.12) were less and not statistically
significant.
Of the 76 patients who received chemotherapy as first-line
treatment for advanced disease, 33 (43%) responded (seven
complete remission, 14 partial remission, 12 stable disease). In
these patients, PMN-E levels, neither when analysed as a
continuous nor as a dichotomised variable, were significantly
related with the rate of response, duration of response, or the
length of progression-free or postrelapse survival.
Multivariate analysis for response to tamoxifen treatment
in advanced disease
The independent relation of PMN-E levels with the rate of response
to tamoxifen treatment in advanced breast cancer was studied
using multivariate logistic regression analysis (Table 2). High
levels of PMN-E were associated with a poor rate of response
(OR¼0.45, P¼0.01). In addition to PMN-E status, premenopausal
status, a short DFI, and ER negativity were associated with a poor
response rate in the multivariate analysis. In separate multivariate
analyses in which PMN-E was added as a dichotomised variable
and ER as a continuous variable to the model, the contributions of
ER (OR, 1.30; 95% CI, 1.15–1.48; Po0.001) and PMN-E (OR, 0.47;
95% CI, 0.25–0.89; P¼0.02) were statistically significant as well.
However, when PMN-E was added as a continuous instead of a
dichotomised variable to the multivariate model shown in Table 2,
its contribution was not statistically significant (P¼0.31).
Furthermore, there was no statistically significant interaction
between categorically added PMN-E and ER with respect to the
rate of response to tamoxifen treatment.
Response to tamoxifen treatment in ER subgroups of
tumours
We explored the association of PMN-E with the response rate in
the clinically important subgroups of ER-positive and ER-negative
patients. The predictive value of a high PMN-E level for a lower
response rate appeared to be confined to the subgroup of 338
Table 2 Univariate and multivariate analysis for response to first-line tamoxifen therapy in patients with advanced breast cancer
Univariate analysis Multivariate analysis
a
Frequency
Response
rate (%) P OR
b (95% CI)
b P OR
b (95% CI)
b
All patients 387 51
Menopausal status
c
Premenopausal 76 34 1
Postmenopausal 311 55 0.001 2.35 (1.39–3.97) o0.001 2.67 (1.54–4.63)
Age (years)
c
p40 33 42 1
41–55 100 43 1.02 (0.46–2.27)
56–70 155 53 1.52 (0.71–3.26)
>70 99 59 0.11 1.92 (0.86–4.26)
First site of relapse
Soft tissue 57 47 1
Bone 169 54 1.30 (0.71–2.37)
Viscera 161 49 0.58 1.07 (0.58–1.96)
Disease-free interval
o1 year 106 35 1 1
X1 year 281 57 o0.001 2.47 (1.55–3.92) o0.001 2.76 (1.70–4.50)
Adjuvant chemotherapy
No 309 51 1
Yes 78 50 0.86 0.96 (0.58–1.57)
ER status
d
Negative 49 24 1 1
Positive 338 55 o0.001 3.73 (1.88–7.40) 0.001 3.22 (1.57–6.60)
PgR status
d
Negative 95 41 1
Positive 282 55 0.02 1.73 (1.08–2.77)
PMN-E levels
e
Low 331 54 1 1
High 56 32 0.003 0.40 (0.22–0.73) 0.01
f 0.45 (0.24–0.86)
aThe final multivariate model with all factors known included 387 patients.
bOdds ratio (95% confidence interval).
cAt the time of start of first-line
tamoxifen treatment.
dCutoff points: 10fmolmg
 1 protein.
eLow: p20.0ngmg
 1 protein, high: >20ngmg
 1 protein.
fThe increment in w
2 after
adding PMN-E to the model including traditional predictive factors was 6.1.
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level, only 14 (35%) responded compared with 171 (57%) of 298
patients with a low PMN-E level (OR, 0.40; 95% CI, 0.20–0.80;
P¼0.009). In 49 ER-negative patients, the fraction of responding
patients was 24% (eight out of 33) and 25% (four out of 16) for
those with low or high tumour PMN-E levels, respectively (OR,
1.04; 95% CI, 0.26–4.16; P¼0.95).
DISCUSSION
During the past 20 years, the presence of steroid receptors in the
primary breast tumour has been the major guide to the physician
to treat the patients with endocrine therapy. However, the steroid
receptor status of the primary tumour does not fully predict which
patient will benefit or fail from endocrine therapy, and many more
potential cell biological predictive factors have been studied
(reviewed by Klijn et al, 1999, 2002). The expression levels of
several serine proteases, such as uPA, human kallikreins 3 and 10
have been reported to be associated with a poor relapse-free and/or
overall survival in patients with primary breast cancer. Since the
serine protease PMN-E is the only neutral protease that is able to
degrade insoluble elastin (Janoff and Schere, 1968; Baugh and
Travis, 1976), which is a structural component of breast tissues
(Hornebeck et al, 1977), we considered it of interest to study the
clinical relevance of PMN-E in breast cancer. Analogous to other
serine proteases, the tumour level of PMN-E was also shown to be
able to discriminate between primary breast cancer patients with
high and low risk of recurrence (Yamashita et al, 1994, 1995b),
irrespective of whether adjuvant tamoxifen treatment was given
(Yamashita et al, 1995a). Yet, from the latter study, no conclusions
can be drawn with respect to a possible relation between PMN-E
and efficacy of tamoxifen therapy. Recently we showed that
primary breast cancer patients with high tumour levels of uPA and
its inhibitor PAI-1, being classified as high risk for recurrence,
experienced an enhanced benefit from adjuvant chemotherapy
(Harbeck et al, 2002a,b). For patients with advanced breast cancer,
a very limited number of studies (all from our laboratory)
addressing the relation of serine proteases with the efficacy of
systemic treatment are available. In this respect, we showed that
high tumour levels of uPA (Foekens et al, 1995), kallikrein 3
(Foekens et al, 1999), or kallikrein 10 (Luo et al, 2002) were
significantly associated with a poor rate of response to tamoxifen
therapy. In the present study, we investigated the predictive value
of PMN-E for the efficacy of tamoxifen and chemotherapy in
patients with advanced breast cancer. The direct measurable effect
of the therapy on the size of relapse or the development of new
relapses was considered the main end point of the study. This
study is different from those performed in the adjuvant setting in
which all intentionally cured primary breast cancer patients are
evaluated with the development of a relapse as end point. In the
case of nonrandomised patients, the occurrence of a relapse does
not necessarily reflect an association of the marker studied with
the efficacy of adjuvant treatment. Furthermore, response as in
objective response and progressive disease cannot be studied
because by definition there is no measurable tumour in the
adjuvant setting. In the present study analysing the predictive
value of PMN-E in the advanced setting, we corrected for
traditional prognostic and predictive factors, including disease-
free interval, in the multivariable logistic regression analysis for
response to tamoxifen treatment. Thus, the possibility that the
observed predictive value of PMN-E partly reflects its prognostic
value is minimal excluded.
So far, the reason for the observed negative relations between
the levels of PMN-E and ER and PgR, which we also showed in a
larger series of 1143 primary breast cancer patients in which we
studied the prognostic value of PMN-E (Foekens et al, 2003), is not
clear. It may be explained by an inhibition in elastase activity by
oestradiol and progesterone that has been observed in breast
cancer cells grown in vitro (Kao and Stern, 1986). On the other
hand, the amount of immunoreactive PMN-E secreted by breast
cancer cells into culture media was not affected by oestradiol,
which suggested that PMN-E synthesis is oestrogen independent
(Yamashita et al, 1994). The only other laboratory that studied
PMN-E expression in human breast cancer tissues reported a
nonsignificant trend towards a negative correlation between PMN-
E levels and those of ER and PgR in a small series of 62 tumours
(Yamashita et al, 1994). In their subsequent study involving 184
tumours of node-negative patients (Yamashita et al, 1995a), no
significant relation between PMN-E and ER or PgR was found.
However, the statistical method used was different from that of our
study in which we used Spearman rank correlation that is better
suited for evaluating correlations between continuous variables. A
further difference is that we have analysed PMN-E levels in
cytosolic tissue extracts, whereas Yamashita et al (1995a) used
Triton X-100 extracts.
In the present study, high tumour levels of PMN-E were
associated with a poor efficacy of tamoxifen treatment in patients
with advanced disease, independent of the traditional predictive
factors menopausal status, disease-free interval, and hormone
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Figure 1 Progression-free survival (A) and postrelapse survival (B) after
start of first-line tamoxifen therapy in 387 patients with advanced breast
cancer as a function of PMN-E status. Patients at risk are indicated. Cutoff
point used, 20ng PMN-Emg
 1 protein.
PMN-elastase and tamoxifen therapy in breast cancer
JA Foekens et al
1088
British Journal of Cancer (2003) 88(7), 1084–1090 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yreceptor status. From the exploratory subgroup analyses, it
appeared that the association of PMN-E with the type of response
to tamoxifen treatment was exclusively present in patients with
ER-positive tumours. The association of PMN-E with the lengths of
progression-free and postrelapse survival was only of statistical
significance during short-term follow-up. These analyses were
indicated since by taking all the failures during the total follow-up
period into account, the proportional hazards assumption, on
which the Cox regression analysis is based, was violated. Such a
time-dependent relation between cell biological factors and
(relapse-free) survival in primary breast cancer has recently been
observed for PMN-E (Foekens et al, 2003), as well as for clinical
and other biological factors like uPA (Yoshimoto et al, 1993;
Schmitt et al, 1997b; Hilsenbeck et al, 1998). In the present study,
no relation between the tumour PMN-E level and the efficacy of
first-line chemotherapy in patients with advanced breast cancer
was seen, suggesting that possible interfering effects of PMN-E are
overruled by the chemotherapy regimens applied.
The underlying mechanisms explaining why the primary
tumour level of PMN-E is associated with the efficacy of tamoxifen
therapy in advanced disease is unclear. In addition to its described
role in tumour cell invasion and metastasis, the serine protease
PMN-E may, similar as has been suggested for uPA for human
ovarian carcinoma cells (Fischer et al, 1998) and breast cancer cells
(Foekens et al, 1995), provoke cell proliferation via enzymatic
activation of several growth factor (receptor) pathways. In this
respect, the ability of elastase to cleave or activate several growth
factors or receptors, such as EGF and EGF receptor (Di Camillo
et al, 2002), IL-2 and IL-6 receptor (Bank et al, 1999), stromal cell-
derived factor-1 (Valenzuela-Fernandez et al, 2002), supports such
a local elastase-directed growth interfering mechanism.
In summary, our study suggests that a high tumour level of
PMN-E is associated with a poor rate of response to tamoxifen
therapy, and a short progression-free and postrelapse survival.
Thus, patients with low tumour levels of PMN-E may respond
better to tamoxifen therapy. In contrast, since the levels of PMN-E
do not affect the effectiveness of chemotherapy, patients with high
tumour levels of PMN-E might benefit from chemotherapy rather
that from endocrine therapy. The present pilot study is the first to
report the relation between the tumour level of PMN-E and the
efficacy of systemic therapy in patients with advanced breast
cancer. However, confirmatory studies are needed before any
conclusions can be drawn regarding suggestions to be made for the
most promising systemic treatment based on the tumour level of
PMN-E.
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